Revolution Medicines recently reported stellar Phase 3 trial results for its pancreatic cancer drug, sending its stock soaring and validating novel targeted therapies. This breakthrough creates a compelling investment opportunity across the broader oncology sector, particularly for biotechnology firms specializing in genetic mutations and precision medicine.
Published on April 14
Revolution Medicines nearly doubled survival rates for pancreatic cancer patients in a Phase 3 trial — and its stock surged nearly 40% overnight. When one company proves the model works, the whole sector takes notice.
Clinical breakthroughs in oncology have historically triggered waves of institutional funding across the broader sector. The companies in this group could be next in line to attract serious investor attention.
Precision oncology isn't just a trend — it's a fundamental shift in how cancer is treated. Analysts are watching this space closely, and these handpicked stocks sit right at the heart of that transformation.
A landmark Phase 3 clinical trial by Revolution Medicines nearly doubled survival rates for metastatic pancreatic cancer patients, sending its stock up nearly 40%. Our analysts believe this breakthrough signals a new wave of investor confidence in precision oncology — the science of matching targeted treatments to specific genetic mutations. We've built this group around the companies best positioned to ride that momentum.
Precision oncology is a high-growth, high-risk area of investing. The companies in this group are mostly clinical-stage biotechs, meaning they are still developing and testing their treatments rather than selling established products. This makes the potential rewards significant, but also means volatility is part of the journey. This basket is best suited as a tactical, growth-focused allocation within a broader portfolio.
Every stock in this group was handpicked by professional analysts for its direct connection to the precision oncology theme — whether through gene editing, synthetic lethality, targeted antibody therapies, or specialised cancer diagnostics. These aren't random biotech picks; they represent companies working on the very frontier of personalised cancer medicine, selected for their scientific relevance and potential to benefit from the current surge in sector momentum.
This basket's total market capitalisation is 7,521.31419 and is concentrated among a few large-cap constituents, giving it a largely large-cap profile.
IDYA: $2.88B
RPTX: $113.38M
PRME: $660.82M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
IDEAYA BIOSCIENCES INC
IDYA
Current Price
$42.32
Specialising in synthetic lethality and targeted therapies for molecularly defined solid tumours, IDEAYA Biosciences perfectly captures the precision ...
Specialising in synthetic lethality and targeted therapies for molecularly defined solid tumours, IDEAYA Biosciences perfectly captures the precision medicine oncology theme.
SpringWorks Therapeutics Inc
SWTX
Current Price
$46.99
Advancing targeted therapy product candidates for specific solid tumours positions SpringWorks Therapeutics as a key player in the precision medicine ...
Advancing targeted therapy product candidates for specific solid tumours positions SpringWorks Therapeutics as a key player in the precision medicine oncology market.
Repare Therapeutics Inc
RPTX
Current Price
$1.07
Repare Therapeutics utilises a proprietary CRISPR-enabled platform to discover targeted cancer therapies focused on genomic instability, fitting perfe...
Repare Therapeutics utilises a proprietary CRISPR-enabled platform to discover targeted cancer therapies focused on genomic instability, fitting perfectly into the precision oncology sector.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+319.53%
On average, analysts expect assets in this group to grow 319.53% over the next year.
14 of 16 assets in this group are rated Buy by professional analysts.
